# Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

> **NCT05960240** · PHASE1 · COMPLETED · sponsor: **Arbutus Biopharma Corporation** · enrollment: 128 (actual)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** AB-101
- **DRUG:** Placebo
- **DRUG:** Nucleos(t)ide Analogue

## Key facts

- **NCT ID:** NCT05960240
- **Lead sponsor:** Arbutus Biopharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-30
- **Primary completion:** 2025-12-04
- **Final completion:** 2026-02-09
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05960240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05960240, "Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05960240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*